# Optimedica

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/optimedica

- Industry: Medical Devices & Equipment
- Headquarters: Santa Clara, US
- Website: www.optimedica.com
- Total disclosed funding: $95M
- Latest round: Series E (Nov 14, 2012)
- Investors on record: 5

## About

Optimedica focuses on developing innovative surgical solutions for cataract treatment, aiming to enhance surgical outcomes and improve patient vision through advanced technology and surgical tools.Optimedica, founded in 2004 in Santa Clara, US, specializes in ophthalmic surgical technology. The company was acquired by Abbott Laboratories on July 15, 2013, for USD 250 mn, with an additional USD 150 mn contingent on achieving specific milestones. Optimedica has completed a total of 8 deals since its inception, consolidating its position in the healthcare market.Optimedica offers advanced cataract surgery solutions, including a versatile suite of surgical products designed to improve patient outcomes. Their core offerings feature a range of intraocular lenses (IOLs), such as the TECNIS™ Toric lenses, tailored for astigmatic patients, along with tools like the TECNIS™ Toric Calculator that aids healthcare providers in lens selection. These products cater to ophthalmologists and eye care professionals across various markets, including North America, Europe, and Asia, focusing on enhancing the quality of life for patients with cataracts.Optimedica generates revenue through direct sales of its cataract surgery products and services to healthcare providers, primarily hospitals and surgical facilities. Their business-to-business (B2B) model relies on transactions involving IOLs and surgical instruments, with pricing reflecting the advanced technology of their offerings. Notable products include the TECNIS™ line of intraocular lenses, which are integral to their portfolio, emphasizing the importance of partnerships within the healthcare sector.Following the acquisition by Abbott Laboratories, Optimedica plans to leverage the funding from this transaction to accelerate its research and development efforts. The company is expected to expand its product line with new surgical technologies aimed at improving cataract treatments and enhancing patient outcomes. Additionally, Optimedica anticipates entering new geographic markets in the coming years, further solidifying its presence in the ophthalmic surgical landscape.

## Funding rounds

- Series E, Nov 14, 2012, $35M — Alloy Ventures, Kleiner Perkins, BlackRock Private Equity Partners (PEP), DAG Ventures, SG Growth Capital
- Series D, Oct 13, 2009, $5.2M — Kleiner Perkins
- Series D, Aug 18, 2009, $25M — Alloy Ventures, Kleiner Perkins, DAG Ventures
- Series C, Mar 26, 2008, $16M — Alloy Ventures, Kleiner Perkins, DAG Ventures
- Series B, Mar 1, 2006, $6.9M — Alloy Ventures, Kleiner Perkins
- Series A, Jan 1, 2006, $6.9M — Alloy Ventures, Kleiner Perkins

## Investors

- Alloy Ventures (https://capitalatlas.ai/funds/alloy-ventures) — Series A, Series B, Series C, Series D, Series E
- Kleiner Perkins (https://capitalatlas.ai/funds/kleiner-perkins) — Series A, Series B, Series C, Series D, Series E
- DAG Ventures (https://capitalatlas.ai/funds/dag-ventures) — Series C, Series D, Series E
- BlackRock Private Equity Partners (PEP) (https://capitalatlas.ai/funds/blackrock-private-equity-partners-pep) — Series E
- SG Growth Capital (https://capitalatlas.ai/funds/sg-growth-capital) — Series E